Zoetis Inc. (ZTS)
Zoetis Earnings Top Analysts' Forecasts
Zoetis (ZTS -8.79%), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded the consensus estimate of $1.36.
Zoetis (ZTS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis (ZTS) Tops Q4 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.24 per share a year ago.
Zoetis forecasts 2025 profit, revenue below estimates; shares fall
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading.
Phibro Animal Health Is Cruising With Its Recent Zoetis Acquisition
Phibro Animal Health delivers animal health and nutritional solutions through feed additives, vaccines, and performance products. The Zoetis acquisition added 37 product lines, driving a 24% increase in net sales and 64% growth in adjusted EBITDA. The company projects strong revenue growth in 2025 with expanding margins and updated EPS guidance.
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Zoetis (ZTS) stood at $172.24, denoting a +0.17% change from the preceding trading day.
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) closed at $165.02 in the latest trading session, marking a +0.94% move from the prior day.
Zoetis (ZTS) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Wall Street Journal Vs. Zoetis
The Wall Street Journal released an article claiming that Zoetis' OA pain drug (Librela) is not safe. I go over these claims and explain why I believe they are unfounded. Librela might face a label change soon, but I don't think there's any reason to worry. I explain why.
